16
total announcements
532331.BO · 15 min delayed
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced its participation in two investor conferences on September 16 and 28, 2026, with Jefferies India Forum and PL Capital Mid & Small Cap Conference, respectively. The meetings will be held at Oberoi, New Delhi, and Trident, BKC, Mumbai. The company confirms that the discussions will be based on already published information.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced that it will transfer unclaimed dividends to the Investor Education and Protection Fund (IEPF) as per the Companies Act, 2013, if shareholders do not claim their dividends within a specified timeframe.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a significant acquisition of shares by Aayush Agrawal, trustee, and other related parties.
Ajanta Pharma Ltd
Ajanta Pharma Ltd's promoter, Ravi Agrawal, has released a pledge on 6,910 equity shares of the company, citing excess pledge as the reason.
Ajanta Pharma Ltd
Ravi Agrawal, a promoter of Ajanta Pharma Ltd, has released a pledge on 54,796 equity shares of the company, citing 'excess pledge' as the reason.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced its participation in two investor conferences: Nuvama India Conference 2026 in Singapore and Hong Kong, and Motilal Annual Global Conference in Mumbai.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has uploaded the written transcript of its earnings call held on 30th July 2026 on its website, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced the publication of its unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has uploaded the audio recording of its earnings call held on 30th July 2026 on its website, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has allotted 23,400 fully paid-up equity shares of Rs. 2/- each upon exercise of options, increasing the paid-up capital to Rs. 24,99,18,048.
Ajanta Pharma Ltd
Ajanta Pharma Ltd announced the record date for determining shareholders eligible for the 1st interim dividend, as per Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced its Q1 FY 2027 results, with revenue up 25% and PAT up 31% YoY. The company has also declared an interim dividend of Rs. 32 per share, amounting to Rs. 400 cr. The company's India branded generic segment has exceeded IPM growth by 36%, driven by new launches and volumes.
Ajanta Pharma Ltd
Ajanta Pharma Ltd reported a 25% increase in revenue and 31% increase in PAT for Q1 FY 2027, with a dividend of Rs. 32 per share declared.
Ajanta Pharma Ltd
Ajanta Pharma Ltd reported Q1 FY 2027 results, with revenue up 25% and PAT up 31% YoY. The company declared an interim dividend of Rs. 32 per share, amounting to Rs. 400 cr. The company's India branded generic segment exceeded IPM growth by 36%.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has made a disclosure under SEBI (SAST) Regulations, 2011, regarding a substantial acquisition of shares by Aayush Agrawal, trustee, on July 29, 2026.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced a revised timing for its earnings conference call scheduled to be held on July 30, 2026, after the board meeting. The call will now take place at 4:15 p.m. IST, and the company will release its Q1 FY 2027 unaudited financial results on the same day at 4:15 p.m. IST.